Medical Evacuation

Showing 156 articles
Business

Medical Properties Trust Shifts HQ to Alabama, Signaling Strategic Focus on Core U.S. Healthcare Portfolio

Medical Properties Trust (NYSE: MPW), a major healthcare real estate investment trust, is relocating its corporate headquarters to Birmingham, Alabama. The move is seen as a strategic effort to streamline operations and deepen ties with its primary U.S. hospital network, lenders, and investors, amid an evolving landscape for hospital ownership and healthcare infrastructure.

Business

Medical Properties Trust Sees Surge in Options Bets Ahead of Earnings, Spotlight on Turnaround Hopes

Ahead of its February 26 earnings report, Medical Properties Trust (NYSE: MPW) is witnessing a notable spike in options activity, with call volume soaring to roughly five times its usual level. This surge in speculative interest comes as the healthcare REIT's shares hover around $5.05, showing recent momentum but still grappling with a challenging multi-year performance. Analysts are divided on whether the stock's current price reflects lingering past troubles or is beginning to price in a potential recovery narrative.

World

Rafah Crossing to Reopen Under Tight Controls, Offering Cautious Hope for Gaza

The Rafah border crossing between Gaza and Egypt is set to partially reopen Sunday, marking a fragile step in the U.S.-brokered ceasefire. While offering a lifeline for medical evacuees and displaced families, the operation will be tightly controlled by Israeli, Egyptian, and EU officials, with significant restrictions on the movement of people and goods.

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...